^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
p53MVA
i
Other names: MVA-p53, p53-MVA Vaccine, p53MVA, modified vaccinia ankara, MVAp53, Modified Vaccinia Virus Ankara Vaccine Expressing p53
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
City of Hope, Tara I-O
Drug class:
p53 stimulant
Related drugs:
9d
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
P2, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • MUC16 (Mucin 16, Cell Surface Associated)
|
PD-L1 expression • TP53 mutation • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
2ms
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov)
P1, N=11, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date • Combination therapy
|
TP53 (Tumor protein P53) • MSI (Microsatellite instability)
|
TP53 mutation • TP53 expression • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
4ms
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
P2, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • MUC16 (Mucin 16, Cell Surface Associated)
|
PD-L1 expression • TP53 mutation • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
1year
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov)
P1, N=11, Active, not recruiting, City of Hope Medical Center | N=19 --> 11 | Trial completion date: Dec 2022 --> Dec 2023
Enrollment change • Trial completion date • Combination therapy
|
TP53 (Tumor protein P53) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
|
TP53 mutation • TP53 expression • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
over1year
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
P2, N=29, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting
Enrollment closed • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • MUC16 (Mucin 16, Cell Surface Associated)
|
PD-L1 expression • TP53 mutation • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
2years
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov)
P1, N=19, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2021 --> Dec 2022
Trial completion date • Combination therapy
|
TP53 (Tumor protein P53) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
|
TP53 mutation • TP53 expression • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
2years
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
P2, N=28, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2022 --> Dec 2023 | Trial primary completion date: Jan 2022 --> Dec 2023
Trial completion date • Trial primary completion date • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • MUC16 (Mucin 16, Cell Surface Associated)
|
PD-L1 expression • TP53 mutation • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
3years
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov)
P1, N=19, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2020 --> Dec 2021
Clinical • Trial completion date • Combination therapy
|
TP53 (Tumor protein P53) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
|
TP53 mutation • TP53 expression • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
3years
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
P2, N=28, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
Clinical • Trial completion date • Trial primary completion date • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • MUC16 (Mucin 16, Cell Surface Associated)
|
PD-L1 expression • TP53 mutation • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
4years
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
P2, N=28, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2020 --> Feb 2021 | Trial primary completion date: Feb 2020 --> Feb 2021
Clinical • Trial completion date • Trial primary completion date • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • MUC16 (Mucin 16, Cell Surface Associated)
|
PD-L1 expression • TP53 mutation • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
Share via
